NeuroBo Pharmaceuticals, Inc. (NRBO)
| Market Cap | 118.62M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -21.33M |
| Shares Out | 16.43M |
| EPS (ttm) | 13.03 |
| PE Ratio | 0.46 |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $6.03 |
| Previous Close | $6.18 |
| Change ($) | -0.15 |
| Change (%) | -2.43% |
| Day's Open | 6.13 |
| Day's Range | 5.84 - 6.21 |
| Day's Volume | 39,979 |
| 52-Week Range | 5.02 - 30.00 |
BOSTON, Jan. 6, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company, today announced that on December 31, 2020 it acquired ANA Therapeutic...
NeuroBo Pharmaceuticals (NRBO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
BOSTON, Nov. 13, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifyi...
BOSTON, Aug. 11, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc.
BOSTON, June 16, 2020 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal, disease-modifyi...
About NRBO
NeuroBo Pharmaceuticals, a clinical-stage biotechnology company provides therapies for neurodegenerative and cardiometabolic diseases. Its therapeutics programs include NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, which is focused on developing and commercializing therapies for the treatment of dyslipidemia. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered i... [Read more...]
| Industry Biotechnology | |
| CEO Dr. Jeong Gu Kang Ph.D. | Employees 12 |
| Stock Exchange NASDAQ | Ticker Symbol NRBO |
Analyst Forecasts
According to one analyst, the rating for NRBO stock is "Buy" and the 12-month stock price forecast is 25.00.